Veramed
Veramed, a leading provider of statistical and programming services, is headquartered in Great Britain and operates extensively across Europe and North America. Founded in 2012, the company has quickly established itself within the pharmaceutical and biotechnology sectors, offering a range of services that include data analysis, clinical trial support, and regulatory submissions. What sets Veramed apart is its commitment to delivering high-quality, tailored solutions that meet the unique needs of its clients. With a focus on innovation and efficiency, the company has achieved significant milestones, including rapid growth and a strong reputation for excellence in data management and statistical consultancy. Veramed's dedication to quality and client satisfaction has positioned it as a trusted partner in the industry, making it a notable player in the competitive landscape of clinical research services.
DitchCarbon Score
How does Veramed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Veramed's score of 6 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Veramed's reported carbon emissions
Veramed, headquartered in the United Kingdom, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by 2030, using 2022 as the base year. This target has been validated through a streamlined process for small and medium-sized enterprises (SMEs) and aligns with the necessary reductions to limit global warming to 1.5°C. In addition to its Scope 1 and Scope 2 commitments, Veramed is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. These initiatives reflect Veramed's dedication to addressing climate change and contributing to a more sustainable future within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Veramed is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
